It’s Differentiate Or Perish At MedImmune’s Oncology iMED
Executive Summary
While the greatest area of growth in Medimmune’s oncology innovative medicines unit is immune-modulated therapies, the company is working on a number of other candidates with unique mechanisms of action and testing them early against standard of care biologics.
You may also be interested in...
MedImmune, Abpro’s Unspecific Plans For Bispecific Antibody Collaboration
The AstraZeneca affiliate and the Boston-area synthetic biology specialist are creating a spinout to develop a bispecific antibody targeting Ang2 and VEGF for undisclosed indications. Cancer and wet age-related macular degeneration seem likely areas of focus.
MedImmune Pipeline Primed To Produce
MedImmune, the biologics arm of performance-challenged AstraZeneca, is poised to lead the parent company into more prosperous times, with positive signals coming from Phase II trials in oncology and asthma and a stake in cancer immunotherapies.
Forest Files Memantine/Donepezil Fixed Combination For Alzheimer’s
Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.